Does Systemic Immune Inflammation Index Predicts Survival In Diffuse Large B Cell Lymphoma Patients?

Abstract

Objective: The systemic immune inflammation index has been considered a novel prognostic biomarker in several malignant tumors. The aim of the current study was to determine the association between the systemic immune inflammation index and prognosis of patients with Diffuse Large B Cell Lymphoma. Material and Method: The study included 101 patients diagnosed diffuse large B cell lymphoma. Receiver operating characteristic (ROC) curve analysis was used to determine the optimal cut-off value of the systemic immune inflammation index for predicting survival. Results: The results of ROC curve analysis showed a cut-off value for the systemic immune inflammation index of 500. No statistically significant difference was determined between the groups with systemic immune inflammation index ≤ 500 and >500 groups in respect of overall-survival and progression-free survival. The mortality risk was determined to be significantly higher in patients with systemic immune inflammation index ≤ 500 (p:0.017). There was no significant relationship between the systemic immune inflammation index values and lactat dehydrogenase, age, R-IPI risk groups,ECOG performance status, and disease stage. Conclusion: The results of this study demonstrated that there is no association between the systemic immune inflammation index and survival in patients with diffuse large B cell lymphoma. Larger prospective studies are needed to investigate the association between the systemic immune inflammation index and Diffuse Large B Cell Lymphoma.